Premium
New Modalities for Challenging Targets in Drug Discovery
Author(s) -
Valeur Eric,
Guéret Stéphanie M.,
Adihou Hélène,
Gopalakrishnan Ranganath,
Lemurell Malin,
Waldmann Herbert,
Grossmann Tom N.,
Plowright Alleyn T.
Publication year - 2017
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201611914
Subject(s) - modalities , scope (computer science) , small molecule , computational biology , drug discovery , therapeutic modalities , computer science , oligonucleotide , nanotechnology , biology , bioinformatics , medicine , dna , biochemistry , materials science , social science , sociology , programming language , physical therapy
Our ever‐increasing understanding of biological systems is providing a range of exciting novel biological targets, whose modulation may enable novel therapeutic options for many diseases. These targets include protein–protein and protein–nucleic acid interactions, which are, however, often refractory to classical small‐molecule approaches. Other types of molecules, or modalities, are therefore required to address these targets, which has led several academic research groups and pharmaceutical companies to increasingly use the concept of so‐called “new modalities”. This Review defines for the first time the scope of this term, which includes novel peptidic scaffolds, oligonucleotides, hybrids, molecular conjugates, as well as new uses of classical small molecules. We provide the most representative examples of these modalities to target large binding surface areas such as those found in protein–protein interactions and for biological processes at the center of cell regulation.